Real-world Study of the Safety and Efficacy of Pembrolizumab in the Treatment of Advanced Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2024.106.29
- VernacularTitle:帕博利珠单抗治疗晚期非小细胞肺癌安全性和有效性的真实世界研究
- Author:
WAN NING
1
,
2
,
3
;
WANG BING
;
GUO YA
;
HE ZIJIAN
;
YANG CHEN
;
YANG NING
;
LU LIQING
;
LIANG HONGYI
;
XIAO WEIBIN
;
YANG DANDAN
;
CHEN ZHUOJIA
;
FANG WENFENG
;
LIANG WEITING
Author Information
1. 510010 广州,中国人民解放军南部战区总医院临床药学科
2. 510515 广州,南方医科大学药学院
3. 510006 广州,广州中医药大学药学院
- Keywords:
Real-world data;
Pembrolizumab;
Lung neoplasms;
Safety;
Efficacy
- From:
Chinese Journal of Lung Cancer
2024;27(10):745-754
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Pembrolizumab(PEM)has been shown to be effective in clinical trials for the treatment of advanced non-small cell lung cancer(NSCLC),but clinical trials were based on cohorts of patients selected on specific criteria,and whether the findings are consistent with real-world patients is debatable.The aim of this study is to evaluate the efficacy and safety of PEM in the treatment of advanced NSCLC based on real-world data.Methods A retro-spective collection of real-world data from patients with advanced NSCLC receiving PEM was conducted.Propensity score matching was used to eliminate inter-group differences and assess the efficacy and safety of PEM compared to chemotherapy.Results Among 450 matched patients,the incidence rates of any-grade adverse events were 79.87％in the PEM group and86.71％inthe chemotherapy group,while the incidence rates of grade＞3 adverse events were 4.03％and 7.31％,respectively.The objective response rates were 48.63％for PEM and 36.00％for chemotherapy(P=0.011).The median progression-free survival was 15.5 months for PEM and 8.8 months for chemotherapy(P＜0.001),and the median overall survival was not reached for PEM and 26.2 months for chemotherapy(P＜0.001).Conclusion PEM treatment for advanced NSCLC demonstrates favorable survival outcomes and acceptable safety in real-world clinical practice.
